Xlife Sciences AG (XSWX:XLS) EBIT: CHF-31.41 Mil (TTM As of Dec. 2025)


XSWX:XLS Xlife Sciences AG XSWX:XLS
50 GF Score
Price CHF20.90
GF Value CHF7.30
Valuation Significantly Overvalued
! 13 Warning Signs
View Full Analysis

What is Xlife Sciences AG EBIT?

Xlife Sciences AG XSWX:XLS -11.06% 50 EBIT is CHF-31.41 Mil as of Dec. 2025. GuruFocus rates XSWX:XLS with a GF Score™ of 50/100 and a GF Value™ of CHF7.30 (Significantly Overvalued). The stock has 13 warning signs investors should review.

Xlife Sciences AG's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was CHF-23.46 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-31.41 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Xlife Sciences AG's annualized ROC % for the quarter that ended in Dec. 2025 was -7.47%. Xlife Sciences AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -2,697.21%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Xlife Sciences AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -11.84%.

Xlife Sciences AG  (XSWX:XLS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Xlife Sciences AG's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-44.252 * ( 1 - 10.02% )/( (535.284 + 530.153)/ 2 )
=-39.8179496/532.7185
=-7.47 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=536.257 - 0.921 - ( 0.052 - max(0, 12.158 - 13.115+0.052))
=535.284

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=517.117 - 0.341 - ( 1.051 - max(0, 14.93 - 1.553+1.051))
=530.153

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Xlife Sciences AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-46.918/( ( (0.211 + max(2.529, 0)) + (0.739 + max(-8.157, 0)) )/ 2 )
=-46.918/( ( 2.74 + 0.739 )/ 2 )
=-46.918/1.7395
=-2,697.21 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(9.416 + 0.046 + 0.081000000000001) - (0.921 + 0 + 6.093)
=2.529

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.094 + 0.029 + 0.014) - (0.341 + 0 + 7.953)
=-8.157

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Xlife Sciences AG's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-31.411/265.323
=-11.84 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xlife Sciences AG EBIT Related Terms

Xlife Sciences AG EBIT Historical Data

* Premium members only.

The historical data trend for Xlife Sciences AG's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xlife Sciences AG EBIT Chart

Xlife Sciences AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial 53.69 4.73 4.92 24.44 -31.41

Xlife Sciences AG Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.61 -4.38 28.82 -7.95 -23.46

XSWX:XLS vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Xlife Sciences AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xlife Sciences AG EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Xlife Sciences AG's EV-to-EBIT falls into.


XSWX:XLS
50GF Score
Xlife Sciences AG XSWX:XLS
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xlife Sciences AG EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-31.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of CHF-31.41 Mil mean?
Xlife Sciences AG (XSWX:XLS) has a EBIT of CHF-31.41 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Xlife Sciences AG.
Is Xlife Sciences AG's EBIT too high?
Xlife Sciences AG's current EBIT is CHF-31.41 Mil. Overall, Xlife Sciences AG has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's EBIT compare to VRTX and REGN?
Xlife Sciences AG's EBIT of CHF-31.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Xlife Sciences AG. Xlife Sciences AG's current EBIT is CHF-31.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.30, compared to a current price of CHF20.90 — trading 186.3% above its estimated fair value. The current EBIT is CHF-31.41 Mil. Xlife Sciences AG's overall GF Score™ is 50/100 with 13 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current EBIT is CHF-31.41 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?

Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued. The current stock price of CHF20.90 is trading 186.3% above its estimated GF Value™ of CHF7.30. GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.

Key valuation signals for XSWX:XLS:

  • EBIT: CHF-31.41 Mil
  • GF Value™: CHF7.30 vs. price of CHF20.90 (186.3% above fair value)
  • GF Score™: 50/100 with 13 warning signs

No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xlife Sciences AG Business Description

Other Exchanges XLSz:UKXLS:Germany
Address Talacker 35, Zurich, CHE, 8001
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
50GF Score

Get the complete analysis for XSWX:XLS

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF20.90
Price
CHF7.30
GF Value